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Yeast endoplasmic reticulum (ER) vesicle protein Erv46p is a novel
membrane protein involved in transport through the early secre-
tory pathway. Investigation of mammalian Erv46 (mErv46) reveals
that it is broadly expressed in tissues and protein-secreting cells. By
immunofluorescence microscopy, mErv46 displays a crescent-
shaped perinuclear staining pattern that is characteristic of the
Golgi complex. Quantitative immunoelectron microscopy indicates
that mErv46 is restricted to the cis face of the Golgi apparatus and
to vesicular tubular structures between the transitional ER and
cis-Golgi. Minor amounts of mErv46 reside in ER membranes and
later Golgi cisternae. On Brefeldin A treatment, mErv46 redistrib-
utes to punctate structures that costain for ERGIC53. Depletion of
mErv46 protein by RNA interference caused no apparent structural
changes in the intermediate compartment or Golgi complex. These
findings place mErv46 in a group of itinerant proteins that cycle
between the ER and Golgi compartments such as ERGIC53 and the
p24 proteins.
In mammalian cells, secretory protein transport from theendoplasmic reticulum (ER) to the Golgi complex proceeds
through the morphologically distinct membrane structures of the
transitional ER to vesicular tubular elements that then appear to
migrate toward and merge with the cis face of the Golgi (1, 2).
Transport through these early compartments of the secretory
pathway relies on a series of protein sorting and membrane
fusion events that are mediated by coat protein complexes and
fusion catalysts (3, 4). Coat protein complex II (COPII) gener-
ates anterograde vesicles at transitional ER sites that then fuse
with or form vesicular tubular structures adjacent to ER exit
sites. In a counter membrane flow, coat protein complex I
(COPI) mediates retrograde transport from the Golgi and from
vesicular tubular elements back to the ER. These vesicular
tubular elements, also known as the ERGIC (ER–Golgi inter-
mediate compartment; ref. 5), appear to be formed by fusion of
ER-derived vesicles with one another or with existing vesicular
tubular structures. Peripheral segments of the ERGIC then
appear to mature into new cis-Golgi cisternae as COPI recycles
vesicle proteins back to the ER (6). Although morphologically
described, many questions remain concerning the molecular
mechanisms that govern overall organization of the early secre-
tory pathway.
Genetic and biochemical studies in yeast have contributed
significantly to our understanding of the components and mech-
anisms underlying transport between the ER and Golgi com-
partments (7). Indeed, COPII was first identified and charac-
terized in yeast (3). Subsequent isolation of in vitro-generated
COPII vesicles from yeast ER has allowed for the identification
of abundant ER vesicle (Erv) proteins (8). These proteins
include members of the p24 protein family, such as Emp24p (9)
and Erv25p (10), as well as SNARE proteins, the sorting factors
Erv14p and Erv29p, and the Erv41p–Erv46p complex (8, 11, 12).
Erv proteins are integral membrane species that cycle between
the ER and Golgi compartments and are conserved among
eukaryotes. Many of the ERV genes are dispensable for yeast
growth but, when mutated, influence protein sorting andor
transport in the early secretory pathway.
To date, the ultrastructural localization of only a few proteins
that cycle between the mammalian ER and Golgi has been
examined in detail. Specifically, the subcellular distribution
patterns for the KDEL receptor, ERGIC53, the p24 complex,
and some of the ER–Golgi SNARE proteins have been docu-
mented (13–16). In contrast, none of the mammalian homologs
of the newly described yeast Erv proteins has been characterized.
Given that Erv proteins are widespread in nature and influence
ER–Golgi transport in yeast, we hypothesize that they are
important components of the early secretory pathway in mam-
malian cells. Here we investigate a representative mammalian
Erv protein, mouse Erv46 (mErv46), to determine its tissue
distribution, subcellular localization, and function. We find that
mErv46 is not required for the overall structural integrity of the
early secretory pathway and speculate that mErv46 influences
movement of cargo through this pathway.
Materials and Methods
Antibodies. The mERV46 cDNA in the pT7T3D-Pac vector was
obtained from Research Genetics (Huntsville, AL), I.M.A.G.E.
Consortium (LLNL) clone ID 480257 (17). A fragment encoding
the luminal domain of mErv46 (amino acid residues 98–272) was
amplified from this plasmid by using primers mERV46-pQE-F2
(5-CGCGGATCCCTGGATGTGGAACACAACCTGTTC-
3) and mERV46-pQE-R (5-CCCAAGCTTGGCTTGGGGT-
GCAGTCACGTTGG-3). The product was inserted into the
BamHI and HindIII restriction sites of vector pQE-30 (Qiagen).
After induction by isopropyl -D-thiogalactoside, the 6 histi-
dine-tagged amino-terminal fusion protein was purified on a
Ni-nitrilotriacetic acid agarose column (Qiagen) as recom-
mended by the manufacturer. This recombinant protein was used
to immunize rabbits according to standard procedures (18). For
affinity purification, mErv46 fusion protein was coupled to an
Affigel-15 matrix (Bio-Rad), and mErv46-specific antibodies
were purified as described (18).
The Sec23p antibody has been described (19). Mouse mono-
clonal antibodies were purchased from Sigma (tubulin and
actin), BD Transduction Laboratories (GM130), and StressGen
Biotechnologies (Victoria, BC, Canada; Ig heavy chain binding
protein, BiP). Mouse monoclonal ERGIC53 antibody (no. G1
93) was a gift from H. P. Hauri (Biozentrum, Basel), and mouse
monoclonal trans-Golgi network (TGN)38 antibody (no. 2F7.1)
was a gift from G. Banting (University of Bristol, Bristol, U.K.).
Secondary antibodies for immunocytochemistry were from Bio-
sys (Compiegne, France), Abcam (Cambridge, U.K.), Molecular
Probes, and Vector Laboratories. Protein A-gold conjugates
were prepared in our laboratory.
Abbreviations: ER, endoplasmic reticulum; COPI, coat protein complex I; COPII, coat protein
complex II; ERGIC, ER–Golgi intermediate compartment; Erv, ER vesicle; mErv46, mouse Erv
protein 46; BFA, brefeldin A; TGN, trans-Golgi network; BiP, Ig heavy chain binding protein.
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RNA Interference Experiments. The mErv46 mRNA was targeted
as described (20) with the sequence 5-AAGGUGGCCG-
GAAACUUCCACdTdT-3. Purified and annealed double-
stranded RNA oligonucleotides were obtained from Dharmacon
Research (Lafayette, CO). HeLa cells were maintained in
DMEM containing 10% FCS, 50 unitsml penicillin, and 50
gml streptomycin and seeded onto glass coverslips or dishes
and grown to 60–80% confluence. For each transfection, 4 l of
oligofectamine reagent (Invitrogen) was mixed with 15 l of
Optimem (Invitrogen). In addition, 10 l of a 20-M double-
stranded RNA oligonucleotide solution or Optimem was mixed
with 175 l of Optimem. These solutions were incubated for 10
min at room temperature, and 19 l of the diluted oligo-
fectamine solution was mixed with 185 l of diluted RNA
oligonucleotide and incubated for 20 min. This transfection
solution was then added dropwise to the culture dish containing
800 l of antibiotic-free DMEM with 10% FCS. Cells were
incubated for 3 h, and an additional 500 l of antibiotic-free
media was added to each dish, followed by 48-h incubation.
Coverslips were then processed for immunofluorescence or the
cells scraped into SDS sample buffer for Western blotting.
Western Blotting. Various mouse tissue lysates were obtained
from Santa Cruz Biotechnology. In addition, mouse livers were
homogenized in 40 mM Hepes, pH 7.5150 mM NaCl1 mM
PMSF1 g/ml leupeptin5 g/ml pepstatin1 mM EDTA in a
glassTeflon homogenizer. The homogenate was centrifuged for
5 min at 1,000  g, and the supernatant was centrifuged for 1 h
at 100,000  g to separate the soluble fraction (S1) from
insoluble material. A portion of the pellet fraction (P1) was
solubilized with 2% Triton X-100 and centrifuged again for 1 h
at 100,000  g to obtain a detergent extract (S2) and detergent-
insoluble pellet (P2). Confluent cultured cells were lysed in 50
mM TrisHCl (pH 7.4)150 mM NaCl1% Triton X-1005 mM
EDTA1 mM PMSF200 kallikrein units aprotinin1 g/ml
pepstatin A. Samples were resolved by standard PAGE and
transferred to poly(vinylidene difluoride) or nitrocellulose mem-
branes. Blots were developed by using the enhanced chemilu-
minescence method (ECL, Amersham Pharmacia).
Light Microscope Immunofluorescence. Cell lines were grown on
glass coverslips and incubated at 37°C. In brefeldin A (BFA)
experiments, the cells were incubated with 6 gml BFA for 1 h.
Control and BFA-treated cells were fixed with 4% paraformal-
dehyde and permeabilized by dehydration with ethanol. Single
labeling was carried out with mErv46 antibodies followed by
FITC-conjugated goat anti-rabbit IgG. Affinity-purified (final
dilution 120) or immune serum (dilution 1100) were both used
with the same results. For double labeling, cells were first
incubated with the mErv46 antibody mixed with either
Fig. 1. (A) mErv46 fractionates as a detergent-soluble membrane protein.
Total liver homogenate (T), soluble extract (S1), total membranes (P1), a 2%
Triton X-100 extract (S2), and Triton X-100-insoluble material (P2) were re-
solved on a 12.5% polyacrylamide gel and detected with the polyclonal
antibody against mErv46. (B) Tissue distribution of mErv46. Tissue homoge-
nates (16 g per lane) were resolved on a 12.5% polyacrylamide gel and
detected with antibodies against mErv46 (affinity purified), Sec23, tubulin,
and actin. The detergent liver extract (S2) from A is included as a positive
control. (C) mErv46 expression in cultured cell lines. Total cell extracts (50 g
per lane) were resolved on a 12% polyacrylamide gel and probed with antisera
against Sec23 and mErv46.
Fig. 2. mErv46 is localized to the cis side of the Golgi complex. NRK and COS
cell lines, cultured on glass coverslips, were incubated at 37°C or treated with
BFA (BFA) at 6 gml for 1 h. Cells were fixed, permeabilized, and processed
for double-labeling immunofluorescence. mErv46 was stained in combination
with well characterized markers of the cis and trans sides of the Golgi complex,
ERGIC53 and TGN38, respectively, and with the ER marker BiP. Rabbit anti-
mErv46 antibody was tagged with FITC-conjugated anti-rabbit IgG (A, D, G, J,
and M). Mouse monoclonal antibodies against TGN38 (B), ERGIC53 (E and H),
or BiP (K and N) were probed with tetramethylrhodamine B isothiocyanate
(TRITC)-conjugated anti-mouse IgG. (Left and Middle) Single-slice confocal
images. (Right) Superimposed red and green labeling. mErv46 and TGN38
signals, shown in A–C, are distinctly separated from each other. In contrast,
mErv46 (D) and the cis-side Golgi marker ERGIC53 (E) extensively overlap, as
shown in the merge image (F). In BFA-treated cells, mErv46 redistributes into
spot-like structures, which still colocalize with ERGIC53 (G–I) but do not
overlap with the ER marker BiP (M–O). (Bar, 5 m.)








ERGIC53 (1500), TGN38 (110), or BiP (150) antibodies.
The labeling was visualized with a mixture of anti-rabbit and
anti-mouse antibodies conjugated to FITC (green) and tetram-
ethylrhodamine B isothiocyanate (red), respectively. Cells were
observed with a laser scanning confocal microscope (LSM 510,
Zeiss).
For RNA interference experiments, cells were fixed in 100%
methanol at 20°C for 10 min and then blocked in PBS with 1%
BSA for 10 min. Cells were then incubated for 30 min at room
temperature with the mErv46 antibody (11,000) mixed with
either GM130 (11,000) or ERGIC53 (11,000). Cells were then
washed for 5 min in PBS and incubated with Alexa594-
conjugated goat anti-mouse and FITC-conjugated goat anti-
rabbit antibodies for 30 min. Cells were washed in PBS for 30
Fig. 3. Immunogold localization of mErv46 on ultrathin cryosections of NRK cells. Shown are Golgi areas in a cis–trans orientation. The region between the
transitional elements (TE) of the ER and the cis side of the Golgi contains numerous vesicular tubular profiles. Gold immunolabeling is observed on vesicular
tubular elements (arrowheads in A) and on the first two cisternae at the cis-Golgi side (arrows in B). The quantitative evaluation of the labeling for NRK and insulin
cells is shown in Tables 1 and 2.
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min, DNA-stained with diamidophenylindole, and mounted with
VECTASHIELD (Vector Laboratories). Immunofluorescent
images were collected with a Hamamatsu (Bridgewater, NJ)
Orca II cooled charge-coupled device camera mounted on a
Zeiss Axioplan 2 microscope, using OPENLAB software (Impro-
vision, Lexington, MA).
Electron Microscope Immunogold Labeling. Cell lines cultured in
plastic dishes were fixed with 1% paraformaldehyde and 0.5%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Fixed cells
were washed with PBS, gently scraped from the dish, and
pelleted in 12% gelatin. Gelatin-embedded pellets were cooled
on ice, cut on small blocks, infused with 2.3 M sucrose, and
processed for ultrathin cryosectioning and immunolabeling ac-
cording to the protein A-gold method (21). The sections were
observed with a 410 LS electron microscope (Philips, Eindhoven,
The Netherlands).
Quantitative Immunoelectron Microscopy. The distribution of
mErv46 was quantified on ultrathin cryosections of NRK and
INS-1 cells. The following cellular compartments were evalu-
ated: (i) The ERGIC, defined as the tubular vesicular membrane
profiles located in the area delimited by transitional elements of
the rough ER and the cis-most Golgi cisterna; (ii) the Golgi
stack, defined as the area containing stacked ribosome-free
cisternae. The lateral rims of the cisternae and the buds were
included in the Golgi stack compartment. The cis-to-trans
distribution of the labeling was evaluated on cross-sectioned
Golgi stacks showing a well defined cis–trans polarity. The
cisternae were numbered from cis (C1) to trans (C5). The
number of gold particles present on each cisterna was expressed
as the percentage of the total number of gold on the stack; (iii)
lateral Golgi vesicles, defined as 50- to 70-nm circular membrane
profiles not connected to cisternae on the section, and located
within 200 nm of the lateral rim of Golgi cisternae; and (iv) the
TGN, defined as the tubulo-vesicular membrane profiles at the
trans-most side of the Golgi stack. The surface density of
labeling was quantified as described (20). All evaluations were
performed on micrographs of Golgi areas enlarged 77,000 times.
Data are means  SEM, obtained on 30 different Golgi areas.
Results
Database searches with the yeast Erv46p sequence revealed one
Erv46p homolog each in Caenorhabditis elegans, Drosophila
melanogaster, and mammals (8). These proteins share a con-
served membrane topology, a dilysine COPI binding motif (22,
23), and eight completely invariant cysteine residues. Most of
Erv46p is luminally oriented with two membrane spanning
segments and short N and C termini that are cytoplasmically
exposed and are required for COPII binding and sorting into
COPII vesicles (24). Overall, mErv46 and yeast Erv46p se-
quences consist of 37% identical and 52% similar amino acid
residues. From the characterization of yeast Erv46p, we hypoth-
esized that mErv46 is located in the early secretory pathway and
involved in secretory processes in mammalian cells (8).
Preliminary studies with antibodies directed against yeast
Erv41p and Erv46p showed a weak perinuclear staining pattern
in CHO and NRK cells. The number of reactive cells was very
small and not sufficient for quantitative experiments. Therefore,
high affinity antibodies were raised against the luminal domain
of mErv46. The antiserum was tested for specificity on Western
blots of mouse liver fractions (Fig. 1A) and purified by affinity
chromatography. A strong band of the anticipated electro-
phoretic mobility was detected in total liver homogenates. This
immunoreactive species was highly enriched in the membrane
pellet fraction. Moreover, a detergent extract generated from the
membrane pellet fraction contained the immunoreactive species
as anticipated for an integral membrane protein. Based on these
results and depletion experiments (Figs. 4 and 5), we conclude
that this antiserum can be used for specific detection of the
mErv46 protein.
We hypothesized that, as a component of the secretory
pathway, mErv46 would be differentially expressed in various
tissues and cultured cell lines depending on their level of
secretory activity. Western blots of tissue homogenates (Fig. 1B)
and cultured cells (Fig. 1C) showed that mErv46 expression level
was indeed tissue specific and, in a majority of cases, similar to
the expression of the COPII subunit Sec23. mErv46 expression
was particularly strong in liver, kidney, and brain but almost
undetectable in heart tissue. Expression was also differential in
various commonly used cell lines, in accordance with mErv46
representation in cDNA libraries used for serial analysis of gene
expression (25). Importantly, mErv46 was readily detected in
INS-1, NRK, COS, CHO, and HeLa cells, enabling us to use
these cell lines for further immunocytochemical studies.
To investigate the subcellular location of mErv46, we first
performed double-labeling immunofluorescence experiments
with the mErv46 antibody on NRK and COS cells (Fig. 2 A–F).
Antibodies against TGN38 and ERGIC53 were used as markers
for the TGN and ERGIC, respectively. The mErv46 antibody
specifically labeled perinuclear structures in NRK cells (Fig. 2 A
and D). mErv46 and TGN38 labeling did not coincide, but
staining was observed in adjacent perinuclear compartments of
NRK cells (Fig. 2 A–C). In contrast, the mErv46 and ERGIC53
staining patterns showed an extensive but incomplete overlap
(Figs. 2 D–F and 5 Upper). Moreover, in double-labeling exper-
iments with the Golgi matrix marker protein GM130, significant
but not total overlap was observed (Fig. 5 Lower). These
observations suggest that mErv46 localizes to the ERGIC and to
the cis pole of the Golgi stack.
Because the yeast Erv41p–Erv46p complex is dynamically
distributed between ER and Golgi membranes, we tested the
Fig. 4. Depletion of mErv46 protein by RNA interference. HeLa cells were
lysed 48 h posttransfection with a double-stranded RNA oligonucleotide, and
total cell lysates were analyzed by Western blot with the mErv46 antiserum.
GM130 and actin are shown as loading controls.





NRK INS-1 NRK INS-1
ERGIC 30  5 51  7 20  4 22  3
Golgi stack
(cisterna 1–5 plus buds)
36  3 27  3 71  4 71  3
Vesicles lateral
to cisternae
9  3 7  3 3  1 1  1
TGN 5  1 4  1 5  2 5  1
See Quantitative Immunoelectron Microscopy for the detailed method-
ological steps. Data are means  SEM.








effects of COPI inhibition by BFA on the distribution of mErv46
in mammalian cells. BFA treatment causes Golgi resident en-
zymes to redistribute to the ER (reviewed in ref. 26), whereas
cycling proteins such as the p24 proteins (27), KDEL receptor
(28), and ERGIC53 (29) are observed in dispersed structures
after BFA treatment. BFA treatment caused a striking disrup-
tion of the Golgi complex, and both mErv46 and ERGIC53
redistributed to scattered punctate structures that showed ex-
tensive overlap (Fig. 2 G–I). Notably, the ER marker BiP and
mErv46 did not colocalize before or after BFA treatment (Fig.
2 J–O). These results demonstrate that the cycling behavior of
mErv46 is comparable to other ERGolgi itinerant proteins such
as ERGIC53 and the p24 proteins.
To more precisely quantify the distribution of mErv46 be-
tween membrane compartments of the early secretory pathway,
immunogold electron microscopy studies were performed (Fig.
3). Gold labeling was frequently seen on vesicular tubular
structures near the cis face of the Golgi complex and on the
cis-most cisternae of the Golgi. Labeling was also observed in
transport vesicles budding from the ER. These observations were
corroborated by quantitative immunoelectron microscopy on
NRK and INS-1 cells. Comparing the distribution over the
ERGIC, the Golgi stack, vesicles lateral to the Golgi stack, and
the TGN, 70% of labeling was observed within the early Golgi
stack. In addition, a significant percentage (20%) localized to
the ERGIC (Table 1). Regarding distribution over the five Golgi
cisternae, the vast majority of mErv46 labeling was observed in
the cis-most cisternae of both cell lines. In contrast, cisternae 3–5
contained very minor amounts (Table 2). Taken together, these
data demonstrate that the bulk of mErv46 localizes to the
ERGIC and to cis-Golgi compartments.
To investigate the influence of mErv46 depletion on ERGIC
and Golgi structure, mErv46 mRNA was targeted for degrada-
tion by RNA interference (20). Typically, transfection efficien-
cies of 90% were observed in HeLa cells 48 h post transfection
with the double-stranded RNA oligonucleotide. Untransfected
and transfected cells were homogenized and analyzed for
mErv46 protein expression by Western blotting using actin as a
loading control (Fig. 4). mErv46 protein was reduced 10-fold
in the transfected cells, whereas the expression level of the Golgi
matrix protein GM130 was unchanged. In immunofluorescence
experiments, these cells did not exhibit any detectable staining
with the mErv46 antibody (Fig. 5), confirming that mErv46
protein expression was efficiently suppressed. Moreover, this
result demonstrated the high specificity of the mErv46 antibody.
Double labeling with the ERGIC53 antibody did not show any
significant difference in expression and subcellular localization
of this protein in the transfected cells. Likewise, the localization
pattern of the Golgi matrix protein GM130 was unchanged.
Taken together, these results demonstrate that mErv46 expres-
sion can be efficiently inhibited by RNA interference. However,
loss of mErv46 function does not appear to have an obvious
effect on the maintenance of ERGIC or Golgi matrix structure.
Discussion
Our localization studies support the hypothesis that mErv46
operates in the early secretory pathway of mammalian cells.
Compared with other integral membrane proteins that act in
these early transport steps, mErv46 displays a similar distribution
pattern as reported for ERGIC53, the KDEL receptor, and p24
proteins (14, 15, 21). Furthermore, BFA causes a similar relo-
calization of this set of cycling proteins to distinct punctate
structures. Costaining experiments revealed a striking separa-
tion of mErv46 from the trans-Golgi-localized protein, TGN38.
Quantitative immunoelectron microscopy further documents
this separation because the concentration of mErv46 falls
sharply from cis- to trans-Golgi cisternae. This boundary, also
delineated by ERGIC53 and the KDEL receptor, likely repre-
sents a functional division of the ERGIC and cis-Golgi from later
Golgi compartments (6).
The subcellular distribution of ERGIC53 and the p24 proteins
are controlled by cytoplasmically exposed C-terminal amino acid
residues (30, 31). In yeast cells, Erv46p is in tight association with
a related protein, termed Erv41p, and this complex cycles
between the ER and Golgi complex. Erv41–Erv46 localization
depends on the C-terminal tails of both subunits, which are
recognized by the COPI and COPII coats. Erv46p contains a
canonical COPI binding motif for retrograde transport, a feature
that is conserved among all of its homologs in other species.
Anterograde transport by COPII requires a hydrophobic COPII
binding motif on Erv41p in concert with a diaromatic motif on
Erv46p (24). Therefore, we propose that the C-terminal tail
sequences of a mammalian mErv41–mErv46 complex are re-
sponsible for its observed localization through dynamic associ-
ations with COPI and COPII. Notably, many of the localization
properties of the mErv41–mErv46 complex are reminiscent of
ERGIC53 and the p24 complex, which have been characterized
in both yeast and mammalian cells (14, 27, 31–33).
The subcellular localization of mErv46 reported in this study
points to a conserved function in yeast and mammalian cells.
Although the precise function of Erv46p in yeast is unclear,
Fig. 5. Depletion of mErv46 by RNA interference does not affect the
expression and subcellular localization of ERGIC53 and GM130 in HeLa cells.
Transfected and control cells were fixed 48 h posttransfection and stained for
DNA (diamidophenylindole, DAPI), mErv46, and ERGIC53 (Upper) or for DNA
(DAPI), mErv46, and GM130 (Lower).
Table 2. Percent distribution of immunogold particles on Golgi
cisternae C1 (cis-most) to C5 (trans-most)
Cells C1 C2 C3 C4 C5
NRK 72  4 21  3 4  1 1  1 1  1
INS-1 65  4 20  3 6  1 8  2 1  1
See Quantitative Immunoelectron Microscopy for the detailed method-
ological steps. Data are means  SEM.
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biochemical and genetic experiments suggest a role for this protein
at the Golgi complex (8). Our RNA interference data indicate that
although mErv46 localizes to the ERGIC and cis-Golgi compart-
ments, loss of mErv46 protein does not alter the expression levels
or localization of marker proteins for these compartments. There-
fore, mErv46 is apparently not required for the maintenance of the
ERGIC compartment or the Golgi matrix, at least under the time
frame we examined. Similarly, Erv46p is not essential for secretory
pathway function in yeast (8).
The parallel properties of mErv46 with ERGIC53 and the p24
proteins suggest related functions. Studies on ERGIC53 indicate
it functions as a transport receptor for soluble secreted glycop-
roteins (33, 34), whereas the p24 proteins act in transport of
specific glycosylphosphatidylinositol-anchored proteins (35).
These activities are apparently not essential for operation of the
secretory pathway but rather influence transport of specific
secretory cargo through this pathway (33, 36). Similarly, our
RNA interference data indicate that mErv46 is not required for
the maintenance of the ERGIC and Golgi compartments in
animal cells. Based on these observations, we propose that
mErv46 acts on protein or lipid species at the ER–Golgi
interface, perhaps in their transport or retrieval within the early
secretory pathway. Further studies in yeast will provide tests of
this proposal. Regardless, the demonstration that mErv46 ex-
pression is widespread and dynamic in animal cells suggests that
it and other Erv proteins could emerge as important components
of the eukaryotic secretory pathway.
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